Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
You may also be interested in...
Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.
Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.
The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.